公开(公告)号：US08846682B2

公开(公告)日：2014-09-30

申请号：US13516543

申请日：2010-12-16

申请人： Eliezer Masliah ,  Edward M. Rockenstein ,  Wolfgang Wrasidlo ,  Igor Flint Tsigelny

发明人： Eliezer Masliah ,  Edward M. Rockenstein ,  Wolfgang Wrasidlo ,  Igor Flint Tsigelny

IPC分类号： A61K31/496 ,  A61K31/52 ,  A61K31/454 ,  A61K31/519 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  C07D403/14 ,  C07D473/00 ,  C07D487/04 ,  C07D417/14 ,  C07D401/14 ,  C07D403/12 ,  C07D417/12 ,  C07D413/12

CPC分类号： C07D417/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D473/00 ,  C07D487/04

摘要： The present invention relates to a compound of formula (I): Wherein R1 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; R2 is an alkyl group with 1 to 18 carbon atoms or a substituted or unsubstituted cycloalkyl or aryl group; R3 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; L is a single bond, an alkyl group having 1 to 6 carbon atoms, NHCO, O, S, NHCONH or NHCOO; X, Y and Z are independently O, N, NH, S or CH; W is a single bond or an alkyl group having from 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt.

摘要翻译： 本发明涉及式（I）化合物：其中R1是取代或未取代的芳族杂 - 或双环或取代或未取代的脂环族杂 - 或双环基团; R2是具有1至18个碳原子的烷基或取代或未取代的环烷基或芳基; R3是取代或未取代的芳族杂环或双环或取代或未取代的脂环族杂 - 或双环基团; L是单键，具有1至6个碳原子的烷基，NHCO，O，S，NHCONH或NHCOO; X，Y和Z独立地为O，N，NH，S或CH; W是单键或具有1至6个碳原子的烷基; 或其药学上可接受的盐或所述化合物或盐的药学上可接受的溶剂化物。

公开(公告)号：US08506959B2

公开(公告)日：2013-08-13

申请号：US11185907

申请日：2005-07-19

申请人： Dale B. Schenk ,  Eliezer Masliah ,  Manuel Buttini ,  Tamie J. Chilcote ,  Edward M. Rockenstein ,  Kate Dora Games

发明人： Dale B. Schenk ,  Eliezer Masliah ,  Manuel Buttini ,  Tamie J. Chilcote ,  Edward M. Rockenstein ,  Kate Dora Games

IPC分类号： A61K39/395

CPC分类号： C07K16/18 ,  A61K38/1709 ,  A61K39/00 ,  A61K2039/505 ,  A61P25/16 ,  A61P25/28

摘要： The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

公开(公告)号：US6107477A

公开(公告)日：2000-08-22

申请号：US167040

申请日：1998-10-06

申请人： Michael A. Whitney ,  Edward M. Rockenstein

发明人： Michael A. Whitney ,  Edward M. Rockenstein

IPC分类号： C12N1/21 ,  C12N15/74 ,  C12Q1/68 ,  C07H21/04 ,  C07H21/02 ,  C12N15/79

CPC分类号： C12N15/74 ,  C12Q1/6897

摘要： A non-optimal translational start site (Kozak) polynuclcotide sequence as set forth in SEQ ID NO:2 is provided. An expression vector for expressing a protein of interest, utilizing the non-optimal translational start site is also provided. Host cells containing the expression vector utilizing the non-optimal translational start site are also provided. A selectable marker encoded by a nucleic acid sequences utilizing the non-optimal translational start site is further provided.

摘要翻译： 提供了如SEQ ID NO：2所示的非最佳翻译起始位点（Kozak）多核苷酸序列。 还提供了用于表达目的蛋白质的表达载体，其利用非最佳翻译起始位点。 还提供了包含使用非最佳翻译起始位点的表达载体的宿主细胞。 还提供了利用非最佳翻译起始位点的核酸序列编码的选择性标记。

公开(公告)号：US20130035342A1

公开(公告)日：2013-02-07

申请号：US13516543

申请日：2010-12-16

申请人： Eliezer Masliah ,  Edward M. Rockenstein ,  Wolfgang Wrasidlo ,  Igor Flint Tsigelny

发明人： Eliezer Masliah ,  Edward M. Rockenstein ,  Wolfgang Wrasidlo ,  Igor Flint Tsigelny

IPC分类号： A61K31/496 ,  C07D403/14 ,  C07D473/00 ,  A61K31/52 ,  A61P25/00 ,  A61K31/454 ,  C07D487/04 ,  A61K31/519 ,  A61P25/16 ,  A61P25/28 ,  C07D417/14 ,  C07D401/14

CPC分类号： C07D417/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D473/00 ,  C07D487/04

摘要： The present invention relates to a compound of formula (I): Wherein R1 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; R2 is an alkyl group with 1 to 18 carbon atoms or a substituted or unsubstituted cycloalkyl or aryl group; R3 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; L is a single bond, an alkyl group having 1 to 6 carbon atoms, NHCO, O, S, NHCONH or NHCOO; X, Y and Z are independently 0, N, NH, S or CH; W is a single bond or an alkyl group having from 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt.

摘要翻译： 本发明涉及式（I）化合物：其中R1是取代或未取代的芳族杂 - 或双环或取代或未取代的脂环族杂 - 或双环基团; R2是具有1至18个碳原子的烷基或取代或未取代的环烷基或芳基; R3是取代或未取代的芳族杂环或双环或取代或未取代的脂环族杂 - 或双环基团; L是单键，具有1至6个碳原子的烷基，NHCO，O，S，NHCONH或NHCOO; X，Y和Z独立地为0，N，NH，S或CH; W是单键或具有1至6个碳原子的烷基; 或其药学上可接受的盐或所述化合物或盐的药学上可接受的溶剂化物。